Ex-ASML, NXP employee sentenced to three year jail term for sharing corporate secrets
ROTTERDAM (Reuters) -A Dutch court on Thursday sentenced a former employee of semiconductor firms ASML and NXP to three years in prison for sharing sensitive company technology with a contact in Russia, in violation of European Union sanctions. The District Court of Rotterdam found the 43-year-old man, German Aksenov, guilty of computer intrusion and illegally providing technical assistance to Russia.
"NXP has a zero-tolerance policy towards data theft and embezzlement. We cooperated with the prosecutor's offices throughout this process", NXP told Reuters in an email.
ASML was not immediately available to comment.
Aksenov was arrested in August 2023 and has remained in custody since. Prosecutors had initially accused Aksenov of selling stolen design manuals for cash and having contact with Russia's FSB intelligence service.
However, the court's final sentence was one year less than the four years prosecutors had demanded, as it could not be proven that Aksenov had been paid for sharing the confidential business information.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
20 minutes ago
- Fox News
Russia strikes US electronics plant in latest attack on Ukraine
Fox News reporter Stephanie Bennett reports on a new airstrike by Russia that impacted a U.S. electronics plant near the Hungary border on 'Special Report.'
Yahoo
38 minutes ago
- Yahoo
Oculis Holding AG (OCS) Reports Q2 Loss, Beats Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.56 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -11.32%. A quarter ago, it was expected that this company would post a loss of $0.51 per share when it actually produced a loss of $0.77, delivering a surprise of -50.98%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. Oculis Holding AG, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.32 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 28.54%. This compares to year-ago revenues of $0.27 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Oculis Holding AG shares have added about 3.2% since the beginning of the year versus the S&P 500's gain of 8.7%. What's Next for Oculis Holding AG? While Oculis Holding AG has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Oculis Holding AG was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.54 on $0.25 million in revenues for the coming quarter and -$2.44 on $0.82 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Phibro Animal Health (PAHC), another stock in the broader Zacks Medical sector, has yet to report results for the quarter ended June 2025. The results are expected to be released on August 27. This maker of animal health products and nutritional supplements is expected to post quarterly earnings of $0.52 per share in its upcoming report, which represents a year-over-year change of +26.8%. The consensus EPS estimate for the quarter has been revised 1% higher over the last 30 days to the current level. Phibro Animal Health's revenues are expected to be $361.15 million, up 32.2% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Oculis Holding AG (OCS) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
41 minutes ago
- Yahoo
Florian Wirtz bats away price-tag questions following Anfield debut
Liverpool's marquee summer signing Florian Wirtz has insisted that his record-breaking price tag will not affect his performances as he prepares for his debut Premier League season. The 22-year-old German attacking midfielder could become the most expensive player in British football history, with the total cost of his transfer from Bayer Leverkusen potentially rising to £116 million if all add-ons are triggered. Despite the scrutiny that comes with such a fee, Wirtz remains calm and focused. Speaking to reporters after Liverpool's pre-season friendly against Athletic Club, the former Bundesliga star made it clear that the financial side of the move is not something that concerns him. 'I just want to play football and how much money the clubs pay between each other, it doesn't matter,' said Wirtz. 'I came because I thought I could fit in this team and I am enjoying staying with these players. I am a player who needs freedom on the pitch and the manager gives it to me.' Wirtz also spoke about his role in the team and how he hopes to contribute in the final third, adding: 'I will try to find the right places to be and the right spaces to get on the ball and to be dangerous and create chances.' Having spent his entire professional career in Germany until now, Wirtz admitted that moving to England has been a significant step, but one he is embracing. He praised the support of his new team-mates, many of whom are also recent arrivals, saying that having others to share the transition with has made settling in easier. 'They tell me it's more intense and more physical and that every player is really strong, really fast,' he said of the Premier League. 'I am really looking forward to play there and experience some differences to Germany, but I think there is also something I can learn that will make me better.' Wirtz added that he is already looking ahead to the team's title defence, knowing the difficulty of repeating such success. 'The big challenge is to win the title again and it is the most difficult thing to do,' he said. 'I will just try to create chances and work hard off the ball and run a lot to help make the team better.' As the season approaches, all eyes will be on Wirtz to see whether he can match the hype and deliver in one of the world's most competitive leagues. If his attitude and early performances are any indication, Liverpool fans may have good reason to be optimistic. 📸 Carl Recine - 2025 Getty Images
